Zynlonta
Zynlonta ingredients
| Active ingredient | Strength |
|---|---|
| Loncastuximab Tesirine | 10 mg/2mL |
What Zynlonta is used for
The FDA lists the approved uses on the official label (below). In the EU, loncastuximab tesirine is approved as Zynlonta for:
Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Zynlonta
- Generic name
- Loncastuximab tesirine
- Made by
- ADC Therapeutics America, Inc.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- FDA approval
- Biologic licence (BLA) BLA761196
- On the US market since
- 2021
Official information
- Zynlonta prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Loncastuximab tesirine)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zynlonta?
Zynlonta (Loncastuximab tesirine) is a cancer medicine made by ADC Therapeutics America, Inc., approved by the US FDA.
What are the ingredients of Zynlonta?
Zynlonta contains Loncastuximab Tesirine (10 mg/2mL).
Is Zynlonta approved in Europe?
The same active substance is approved in the EU as Zynlonta.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA